PMC9733686_01
Chest X-ray (A and B) and computed tomography (C and D) of the case 1 patient on admission to our hospital on day 40 (A and C) and day 52 (B and D). Interstitial shadows in X ray and Ground-glass opacities (GGOs) in CT are found in both lung fields on admission to our hospital on day 40 (A and C). These interstitial shadows and GGOs were increased 12 days later on day 52 (B and D). Both of the lung volumes were also reduced on day 52 (B), compared with on day 40 (A). Arrows indicated the abnormal shadows in chest X-ray and CT, such as interstitial shadows and GGO.
IDR-15-7117-g0001.jpg
PMC9733686_01_IDR-15-7117-g0001.jpg
f0001
Chest X-ray/CT showed massive GGOs in both lung fields (Figure 1A and C), although the SpO2 was 95% by nasal cannula 2 L, and SARS-CoV-2 Ag was increased to >5000 IU again at day 41.  SARS-CoV-2 Ag was increased to >5000 IU again, and she was treated with an HFNC because her chest X-ray/CT were also not improved (Figure 1B and D). She and her family refused mechanical ventilation, and she died on day 60 due to respiratory failure.
PMC9733686_02
Chest X-ray (A-C) and computed tomography (D-F) of the case 2 patient on day 10 (A and D), day 15 (B and E), and day 30 (C and F). GGOs are found in both lung fields on day 10 (A and D). They were worse and lesions, including the densities were increased on day 15 (B and E), but they have finally improved on day 30 (D and F). Arrows indicated the abnormal shadows in chest X-ray and CT, such as interstitial shadows and GGO.
IDR-15-7117-g0002.jpg
PMC9733686_02_IDR-15-7117-g0002.jpg
f0002
COI; IgG-spike protein, 334 IU/mL; and IgG-nucleocapsid protein 5 IU/mL (Table 1). Chest X-ray/CT showed massive GGOs in both lung fields (Figure 2A and D), although SpO2 was 94% by nasal cannula 3 L, and the SARS-CoV-2 Ag was increased to 217.0 IU.  However, his chest X-ray/CT showed severe deterioration, and GGOs were increased on day 15 (Figure 2B and E). On day 30, his chest X-ray and CT were improved (Figure 2C and F), and he could maintain SpO2 of 97% with nasal cannula O2 1 L.